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Abstract: A i m: Th e aim of the study was to assess the diagnostic value of serum concentrations of neu-
trophil gelatinase-associated lipocalin (sNGAL) for the determination of the severity of acute pancreatitis 
(AP) at the early stage of the disease.
M a t e r i a l s  a n d  M e t h o d s: Th e study group consisted of 65 patients (34 men and 31 women), aged 
62.2 ± 16.0, admitted to the Surgery Department of the District Hospital in Sucha Beskidzka, Poland, 
with the diagnosis of AP according to the revised Atlanta classifi cation (2012). sNGAL was measured 
with ELISA at 24, 48 and 72 hours following the onset of AP symptoms. Th e correlations were analyzed 
between sNGAL and clinical, as well as laboratory parameters, used for the assessment of AP severity.
R e s u l t s: Severe AP was associated with higher sNGAL at 24, 48 and 72 hours, while moderately severe 
AP was associated with higher sNGAL at 48 and 72 hours as compared to mild disease. Th e BISAP score ≥3 
during the fi rst 24 hours of hospital stay, and the duration of hospital stay were signifi cantly correlated with 
sNGAL. Also, sNGAL positively correlated with white blood cells, C-reactive protein and fi brinogen and 
negatively with albumin throughout the study. Th e diagnostic accuracy of sNGAL for the diff erentiation 
between mild AP and more severe disease was 75%, 77% and 85% at 24, 48 and 72 hours, respectively. 
C o n c l u s i o n s: Serum NGAL concentrations are associated with infl ammatory markers, BISAP score 
and the severity of AP. sNGAL may serve as an additional prognostic biomarker in the early assessment 
of AP severity.
Key words: acute pancreatitis, neutrophil gelatinase-associated lipocalin, prognostic markers.
Introduction
Nearly 80% of all cases of acute pancreatitis (AP) are mild (MAP — mild acute pan-
creatitis). MAP requires only supportive care, and it generally resolves without any 
complications. However, 20% of patients develop the severe acute pancreatitis (SAP), 
which is a life-threatening disease with a mortality rate of 20–30% [1–4]. Th e mortal-
ity rate is signifi cantly higher in older patients and in patients with BMI ≥30 [2]. At 
early phase of the disease, the mortality is associated with prolonged (lasting longer 
than 48 hours) organ failure (mainly respiratory, circulatory or renal failure) [2, 5–7]. 
In patients with acute kidney disease (AKI) in the course of AP the mortality rate 
reaches 70–80% [8–10]. An early classifi cation of the severity of AP and initiation 
of adequate treatment is decisive for the prognosis as well as for the patient survival 
[11–12]. Th e “therapeutic window” in AP is usually reported to last between the 48 
and 72 hours following the onset of symptoms [5]. On the other hand, despite numer-
ous studies and signifi cant progress in diagnostic techniques, the early determination 
of AP severity remains diffi  cult. Together with clinical assessment, the multi-parame-
ter prognostic scales such as Ranson’s score, Glasgow, Acute Physiology and Chronic 
Health Evaluation  II (APACHE II), or bedside index for severity in AP (BISAP) are 
used for this reason [1,  12]. Simultaneously, the diagnostic value of single laborato-
ry markers are studied in this context. Procalcitonin (PCT) and C-reactive protein 
(CRP) levels are among the most recognized biomarkers [3, 10, 12–13]. Even though 
a signifi cant increase in CRP concentrations is observed in SAP rather than in MAP 
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patients, its peak concentrations are observed relatively late, between the 48th and 72nd 
hour aft er the disease onset [3, 12]. During the fi rst 24 hours of AP, the secretion of 
proteolytic enzymes from activated neutrophils, i.e. polymorphonuclear granulocyte 
elastase (PMN-elastase), or gelatinases is observed [3, 12, 14]. 
Neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin-2, is 
a 25kDa glycoprotein, initially found in activated human neutrophils in a form covalently 
bound to neutrophil gelatinase. Physiologically, NGAL is expressed in low levels in 
kidneys, trachea, lungs, stomach, pancreas and colon; its expression is significantly 
increased under inflammatory conditions and following damage to the endothelial 
cells [14–18]. NGAL is freely fi ltered by the renal glomeruli, and almost completely 
absorbed by the proximal tubules [19–20]. Serum NGAL concentrations depend to some 
extend on age, sex, and liver condition, and correlate with markers of infl ammation 
[18,  21–24]. 
Th e aim of the study was to assess the diagnostic value of serum concentrations 
of NGAL (sNGAL) for the determination of the severity of AP at early stage, i.e. the 
fi rst 72 hours aft er the onset of symptoms of the disease. Also, the correlations were 
analyzed between sNGAL and clinical, as well as laboratory parameters used for the 
assessment of AP severity, including the infl ammatory markers. 
Materials and methods
Th e study group
Th e prospective study included 65 adult patients admitted with the diagnosis of AP, 
undergoing treatment in the Surgery Department of the District Hospital in Sucha 
Beskidzka between January and December 2014. AP was diagnosed according to the 
revised Atlanta classifi cation (2012) [6]. Patients who were admitted later than 24 
hours aft er the onset of symptoms of AP and those who refused to sign the informed 
consent for the study were excluded. 
Depending on the severity of AP, patients were assigned to one of 3 groups [6]. 
Th e fi rst group — mild acute pancreatitis (MAP) included patients in whom no 
organ dysfunction or local complications were observed during the hospital stay. Th e 
second group consisted of patients with moderately severe acute pancreatitis (MSAP), 
with transient organ failure (lasting for less than 48 hours), local complications (i.e. 
acute peripancreatic fl uid, pancreatic pseudocyst, acute necrotic collection, walled-
off  necrosis), and/or exacerbation of comorbidities. Patients persistent organ failure 
(lasting longer than 48 hours) and ≥1 local complications were assigned to the third 
group — severe acute pancreatitis (SAP). 
Th e study was conducted in accordance with the Declaration of Helsinki. Th e 
study protocol was approved by the Bioethics Committee of the Jagiellonian University 
in Cracow (Poland) (approval no. KBET/247/B/2013). 
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Laboratory tests
Blood samples for the laboratory tests were collected at 24, 48 and 72 hours from 
the onset of AP symptoms. Th e routine laboratory tests, including the complete 
blood count (WBC), amylase activity, serum concentrations of urea, creatinine, cal-
cium, C-reactive protein (CRP), albumin, and plasma concentrations of fi brinogen 
were performed the same day in the Medical Diagnostic Laboratory in Sucha Be-
skidzka, Poland. Th e sera for sNGAL determination were frozen within 1 hour of 
blood collection and stored at –70°C no longer than 6 months. Th e sNGAL con-
centrations were measured using the Human Lipocalin-2/NGAL ELISA kit (Bio-
Vendor, Brno, Czech Republic) and the Automatic Micro ELISA Reader ELX 808 
(BIO-TEK® Instruments Inc., Winooski, VT, USA) at the Department of Diagnostics, 
Chair of Clinical Biochemistry, Jagiellonian University Medical College in Cracow, 
Poland.
Statistical analysis
Data are reported as number of patients and percentage of the group for categories, 
and the mean ± standard deviation (SD) or median (lower-upper quartile) for quan-
titative variables, depending on the distribution (the Shapiro-Wilk test was used to 
assess normality). Diff erences between groups were tested with ANOVA or Kruskal-
Wallis ANOVA. Spearman rank coeffi  cient was calculated to assess correlations. Th e 
receiver operating characteristic (ROC) curves were used to assess the diagnostic val-
ue of sNGAL, the areas under the ROC curves (AUC) are reported with 95% confi -
dence intervals (95% CI). All the tests were two-tailed and the results were considered 
signifi cant at p-value of less than 0.05. Th e Statistica 10.0 package (Statsoft  Inc., Tulsa, 
USA) was used for computations.
Results
Relationship between sNGAL and the severity of AP
Th e clinical characteristics of patients with MAP, MSAP and SAP together with the 
results of laboratory tests performed at 24 hours aft er the onset of AP symptoms are 
presented in Table 1. Th e diff erences between groups regarding age, sex, or prevalence 
of comorbidities were not statistically signifi cant. AP aetiology was mostly gallstones 
(33 patients, 51%), alcohol (18 patients, 28%) and hypertriglyceridemia (5 patients, 
8%). Th ere were no signifi cant diff erences in aetiology between MAP, MSAP and SAP 
patients. Th e most prevalent comorbidities included: hypertension (22 patients, 34%), 
ischemic heart disease (18 patients, 28%) and diabetes (10 patients, 15%); 7 patients 
(11%) were diagnosed with lung diseases and 3 (5%) with kidney diseases.
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Table 1. Clinical characteristics of AP patients and laboratory data at admission according to severity of 
the disease.
MAP (n = 46) MSAP (n = 14) SAP (n = 5) p*
Age, years 59 ± 19 64 ± 16 70 ± 19 NS
Males, n (%) 25 (54) 6 (42) 3 (60) NS
Duration of pain until 
admission, hours 12 (6–24) 12 (6–36) 24 (24–48) NS
Duration of hospital stay, 
days 6 (5–7) 12 (10–17) 27 (13–31) <0.001
a,b
BISAP score ≥3 in fi rst 24 h, 
n (%) 0 2 (14) 4 (80) <0.001
c
Comorbidities, n (%) 33 (72) 12 (86) 5 (100) NS
Mortality, n (%) 0 0 3 (60) –
WBC, x103/μL 11.1 (9.2–14.6) 12.4 (10.6–15.3) 10.4 (9.8–18.4) NS
HCT, % 42.5 ± 4.1 43.2 ± 6.7 39.0 ± 7.1 NS
PLT, x103/μL 237 (196–255) 230 (210–267) 128 (121–150) NS
Amylase, U/L 1085 (571–1722) 1038 (772–1917) 1013 (357–1909) NS
Glucose, mmol/L 7.7 (6.4–9.8) 9.1 (7.2–12.2) 13.3 (6.3–15.7) NS
Urea, mmol/L 5.5 (4.1–6.8) 6.7 (5.6–8.4) 13.4 (11.7–15.1) 0.002a
Creatinine, μmol/L 72.7 (63.4–94.8) 90.7 (67.6–113.4) 194.4 (120.0–228.0) 0.008a
Calcium, mmol/L 2.33 ± 0.17 2.32 ± 0.23 2.01 ± 0.34 NS
CRP, mg/L 5.9 (1.9–48.6) 24.4 (9.0–103.2) 191.1 (74.6–258.2) 0.003a
Albumin, g/L 40.6 ± 4.0 39.7 ± 3.9 30.7 ± 8.4 0.030a
Fibrinogen, g/L 2.62 (2.13–3.57) 3.19 (2.27–3.31) 4.46 (3.55–5.38) NS
sNGAL, μg/L 104 (68–139) 226 (191–274) 329 (198–427) 0.007a
* p-value for overall diff erence between the 3 groups; superscript numbers denote signifi cant diff erences in post-
hoc tests: a — between MAP and SAP; b — between MAP and MSAP; c — in all between-groups comparisons
Th e BISAP score during the fi rst 24 h ours of hospital stay, and the duration of 
hospital stay were significantly associated with AP severity (Table 1). There were 
3 deaths among SAP patients aft er 13–31 days of hospital stay (i.e. all are classifi ed as 
late mortality). Also, SAP patients had higher concentrations of urea, creatinine, CRP, 
D-dimer and sNGAL, and lower concentrations of albumin at admission (Table 1, Fig. 1).
Th e concentrations of sNGAL on days 2 and 3 aft er admission were higher in SAP 
and MSAP patients as compared to MAP (Fig. 1, Table 1). Th e highest median sNGAL 
concentrations were detected on day 2 in all groups (Fig. 1), although the time-related 
diff erences were statistically signifi cant only among MAP patients (p = 0.038). 
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Fig. 1. Th e concentrations of sNGAL in patients with mild (MAP), moderately severe (MSAP) and severe 
acute pancreatitis (SAP) at 24 (a), 48 (b) and 72 hours (c) aft er the onset of AP symptoms; p-values are 
shown for signifi cant diff erences in post-hoc tests.
Th e concentrations of sNGAL were signifi cantly correlated with the duration of 
hospital stay and the BISAP score throughout the study (Table 2).
Table 2. Simple correlations between sNGAL and the selected variables at 24, 48 and 72 hours aft er onset 
of AP symptoms.
Variable
24 hours 48 hours 72 hours
R p R p R p
Duration of hospital stay  0.38  0.002  0.54 <0.001  0.43 <0.001
BISAP score  0.39  0.002  0.47 <0.001  0.55 <0.001
WBC  0.46 <0.001  0.64 <0.001  0.58 <0.001
CRP  0.66 <0.001  0.70 <0.001  0.60 <0.001
Fibrinogen  0.51 <0.001  0.40 <0.001  0.34  0.005
Albumin –0.43 <0.001 –0.57 <0.001 –0.60 <0.001
Relationships between sNGAL and selected markers of infl ammation
Signifi cant positive correlations were found between sNGAL and the markers of in-
fl ammation, i.e. WBC, CRP and fi brinogen. Th e correlations with CRP were particu-
larly strong. Also, sNGAL negatively correlated with albumin. All the relationships 
were observed throughout the study (Table 2).
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Diagnostic value of sNGAL in AP
When applying the upper reference limits provided by the manufacturer of the test 
(276 μg/L for women and 169.2 μg/L for men), 15 (23%), 23 (35%) and 21 (32%) pa-
tients had increased sNGAL at admission, on days 2 and 3 of hospital stay, respective-
ly. However, there were no sex-related diff erences in sNGAL concentrations among 
studied patients (p-values from 0.2 at admission to 0.7 on day 2). 
Table 3. Th e diagnostic value of sNGAL for the diff erentiation between MAP and more severe AP (MSAP 
or SAP) at the cut-off  values chosen based on ROC curves analysis and the upper reference limits (URL) 
provided by the manufacturer of the test (i.e. 276 μg/L for women and 169.2 μg/L for men).
Time point* Cut-off  value Sens., % Spec., % PPV, % NPV, % Acc., %
24 hours
ROC: 165 μg/L 63 80 57 84 75
URL 42 84 53 78 72
48 hours
ROC: 183 μg/L 90 72 57 94 77
URL 47 70 39 76 63
72 hours
ROC: 182 μg/L 84 78 62 92 80
URL 53 76 48 80 69
Sens. — sensitivity; Spec. — specifi city; PPV — predictive value of positive result; NPV — predictive value of nega-
tive result; Acc. — accuracy 
* Time aft er the onset of AP symptoms.
In ROC curves analysis, sNGAL assessed at admission enabled the diff erentiation 
between MAP and more severe forms of AP (MSAP or SAP), although the value of 
AUC at admission was lower than on day 2 and 3 of hospital stay (Fig. 2). Th e best 
cut-off  values were close to the upper reference limit provided by the manufacturer 
for men, and signifi cantly lower than the upper reference limit for women.
At admission, using the manufacturer’s upper reference limits to diagnose between 
MAP and MSAP or SAP yielded lower sensitivity but higher specifi city comparing to 
ROC-based cut-off  value. However, on subsequent days, ROC-based values that did 
not diff er between men and women yielded better diagnostic value. 
Discussion
According to the revised Atlanta classifi cation, two phases may be distinguished in 
the course of AP: an early phase — up to the fi rst week, and a late phase thereaft er 
[6, 12]. Th e severity of AP is stratifi ed into mild, moderately severe, and severe [3]. 
Nearly 50% of deaths due to SAP take place in the early phase, in a consequence 
of multiple organ dysfunction syndrome (MODS) [3, 5]. In the present study, serum 
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NGAL concentrations measured early in the course of AP was associated with the 
disease severity. Already at 24 hours following the onset of symptoms of AP, sNGAL 
was signifi cantly higher in SAP than in MAP, and enabled the diff erentiation between 
MAP and more severe disease. Also, sNGAL at 24 hours was positively correlated 
with BISAP score and the duration of hospital stay. Th ere is an emerging literature 
showing the associations between serum, plasma, urine and NGAL concentrations 
and prognosis of SAP [3, 11, 25–26].
Fig. 2. ROC curves presenting the diagnostic value of sNGAL concentrations in diff erentiating between 
MAP and more severe forms of AP (MSAP or SAP) at 24 (a), 48 (b) and 72 hours (c) aft er the onset of AP 
symptoms. Th e selected cut-off  values are highlighted. Th e area under curve (AUC) values are reported 
with 95% confi dence intervals. 
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Increased concentrations of NGAL in serum and in urine have been reported 
in the course of various infectious and non-infectious diseases [14, 17, 24,  27–28]. 
The increased expression of NGAL has been shown in acute and chronic 
inflammatory states, e.g. in acute renal failure, chronic kidney disease, chronic 
obstructive pulmonary disease, sepsis, and acute pancreatitis [9, 14–15, 17, 24, 
28–29]. Th e observed overexpression of NGAL indicates activation of neutrophils, and 
may be considered a symptom of the development of acute systemic infl ammation 
in response to the presence of harmful stimuli, and a symptom of the development 
of complications [3, 11, 17–18, 28]. In the present study, a number of correlations 
between sNGAL and acute phase proteins, i.e. CRP, albumin and fi brinogen, were 
observed. In AP, premature activation of pancreatic enzymes, microcirculatory 
disorders, local gathering of infl ammatory cells, i.e. macrophages and neutrophils, 
as well as the excessive infl ammatory response with production of cytokines and 
infl ammatory mediators initiate a series of processes which, within a short period of 
time, may lead to the development of irreversible changes and death, even in patients 
for whom the prognosis was initially good. Th e rapid, dynamic changes in the course 
of AP make it diffi  cult to create a unifi ed regimen for the assessment and treatment of 
AP patients [9]. At present, the most widely used routine diagnostic procedure for the 
prediction of the severity of AP is, next to imaging examinations and the multifactor 
prognostic scoring systems, measurement of serum CRP and PCT [8, 12–13]. However, 
neutrophils and proteolytic enzymes secreted after the activation of neutrophils 
(neutrophil elastase, gelatinase), play the key role in the infl ammatory cascade in the 
course of AP [3, 12]. Our earlier studies [30] point towards the diagnostic value of 
PMN elastase in the early-phase of AP. PMN elastase was signifi cantly increased in 
AP patients starting from the fi rst day of hospital stay, being one of the early markers 
of the developing infl ammatory state. In turn, Helanova et al. [21] show the diagnostic 
value of NGAL for the evaluation of the intensity of the systemic inflammatory 
response syndrome (SIRS), and for the early prognosis organ dysfunction, mainly 
acute respiratory distress syndrome, and acute kidney  injury [12, 20].
Although the present study shows some usefulness of sNGAL in the early 
prediction of AP severity, the diagnostic value of sNGAL is too low to support the its 
use as a single predictor. Also, its diagnostic accuracy at 24 hours of AP is lowe r than 
at 48 and 72 hours. Aft er 72 hours, the diagnostic sensitivity (84%) and specifi city 
(78%) for the cut-off  value 182 μg/l are similar to other markers of infl ammation, 
e.g. CRP [12]. Also, our data support the need for establishing the appropriate 
cut-off  or decision values, as the use of manufacturer-provided values resulted in 
lower diagnostic utility. 
The low number of patients included and the one-center design are obvious 
limitations of our study. At present, the determination of NGAL in serum is connected 
with methodological limitations, that limit its use as a routine laboratory test. 
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However, also in the light of other reports [25–26], our data indicate the usefulness of 
sNGAL as an additional marker for the stratifi cation of the severity of AP. 
Conclusions
Th e measurement of sNGAL during the early phase of AP enables the diff erentia-
tion between mild and more severe forms of the disease with acceptable diagnostic 
accuracy. Also, sNGAL concentrations in AP patients are correlated with infl amma-
tory markers, BISAP score, and the duration of hospital treatment. Th e present study 
indicates that sNGAL may serve as an additional prognostic biomarker in the early 
assessment of AP severity.
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